Northern Trust Corp Phathom Pharmaceuticals, Inc. Transaction History

Northern Trust Corp

$690 Billion
Q4 2024

A detailed history of Northern Trust Corp transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 397,964 shares of PHAT stock, worth $2.22 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

397,964

Previous 320,775 24.06%

Holding current value

$2.22 Million

Previous $5.8 Million 44.28%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$7.45 - $18.94 $575,058 - $1.46 Million	77,189 Added 24.06%	397,964 $3.23 Million
Q3 2024 Nov 13, 2024	BUY	$10.25 - $19.5 $452,178 - $860,242	44,115 Added 15.95%	320,775 $5.8 Million
Q2 2024 Aug 14, 2024	SELL	$8.97 - $12.05 $58,663 - $78,807	-6,540 Reduced 2.31%	276,660 $2.85 Million
Q1 2024 May 14, 2024	SELL	$6.21 - $11.05 $41,103 - $73,139	-6,619 Reduced 2.28%	283,200 $3.01 Million
Q4 2023 Feb 13, 2024	BUY	$6.99 - $10.71 $147,090 - $225,370	21,043 Added 7.83%	289,819 $2.65 Million
Q3 2023 Nov 13, 2023	BUY	$10.26 - $15.7 $529,313 - $809,963	51,590 Added 23.75%	268,776 $2.79 Million
Q2 2023 Aug 11, 2023	BUY	$7.28 - $14.32 $31,194 - $61,361	4,285 Added 2.01%	217,186 $3.11 Million
Q1 2023 May 15, 2023	BUY	$6.19 - $12.36 $11,463 - $22,890	1,852 Added 0.88%	212,901 $1.52 Million
Q4 2022 Feb 13, 2023	BUY	$9.18 - $11.53 $177,541 - $222,990	19,340 Added 10.09%	211,049 $2.37 Million
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $11,763 - $22,052	1,821 Added 0.96%	191,709 $2.12 Million
Q2 2022 Aug 12, 2022	BUY	$6.2 - $15.5 $68,683 - $171,709	11,078 Added 6.2%	189,888 $1.6 Million
Q1 2022 May 13, 2022	SELL	$11.55 - $20.06 $105,047 - $182,445	-9,095 Reduced 4.84%	178,810 $2.43 Million
Q4 2021 Feb 08, 2022	BUY	$17.83 - $33.15 $32,611 - $60,631	1,829 Added 0.98%	187,905 $3.7 Million
Q3 2021 Nov 15, 2021	SELL	$30.69 - $36.83 $270,072 - $324,104	-8,800 Reduced 4.52%	186,076 $5.97 Million
Q2 2021 Aug 13, 2021	BUY	$32.66 - $39.87 $2.06 Million - $2.51 Million	63,020 Added 47.79%	194,876 $6.6 Million
Q1 2021 May 12, 2021	BUY	$33.86 - $48.68 $18,115 - $26,043	535 Added 0.41%	131,856 $4.95 Million
Q4 2020 Feb 11, 2021	SELL	$33.22 - $50.26 $37,438 - $56,643	-1,127 Reduced 0.85%	131,321 $4.36 Million
Q3 2020 Nov 16, 2020	SELL	$29.24 - $40.19 $321,786 - $442,290	-11,005 Reduced 7.67%	132,448 $4.86 Million
Q2 2020 Aug 14, 2020	BUY	$25.06 - $54.6 $305,606 - $665,847	12,195 Added 9.29%	143,453 $4.72 Million
Q1 2020 May 14, 2020	BUY	$24.65 - $42.83 $414,908 - $720,914	16,832 Added 14.71%	131,258 $3.39 Million
Q4 2019 Feb 14, 2020	BUY	$18.59 - $37.67 $2.13 Million - $4.31 Million	114,426 New	114,426 $3.56 Million

Others Institutions Holding PHAT

# of Institutions

158

Shares Held

68.6M

Call Options Held

52.3K

Put Options Held

635K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $219M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Phathom Pharmaceuticals, Inc. Transaction History